USISTAPIDE
Usistapide is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 10% methyl salicylate pain relief patch | C200263 | 2024-06-27 |
| 1st medxpatch | unapproved drug other | 2025-10-31 |
| 365 whole foods market anticavity/antigingivitis mouthwash | OTC monograph not final | 2022-05-12 |
| 5kind dmso | C200263 | 2025-12-02 |
| 701 dieda zhengtong yaogao medicated | OTC monograph not final | 2019-11-13 |
| 701 dieda zhengtong yaogao medicated plaster | OTC monograph not final | 2014-06-26 |
| abejas y viboras roll on | C200263 | 2025-07-22 |
| absolut skin spf 50 moisturizing sunscreen | C200263 | 2025-06-19 |
| advanced antiseptic citrus | C200263 | 2025-02-20 |
| advanced citrus antiseptic | C200263 | 2025-01-10 |
Show 704 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 3 | — | — | — | 3 |
| Nutritional and metabolic diseases | D009750 | — | — | — | 3 | — | — | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | — | — | — | 2 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 2 | — | — | — | 2 |
| Overweight | D050177 | — | E66.3 | — | 2 | — | — | — | 2 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | 2 | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | — | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | USISTAPIDE |
| INN | usistapide |
| Description | Usistapide is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Small molecule |
| Drug class | microsomal triglyceride transfer protein (MTP) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H](c1ccccc1)N1CCC(c2ccc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)cc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 403989-79-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103860 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 73YSY3U094 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Daytrana – Shire
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Concerta – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Bloxiverz – Avadel Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Medrol – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Methylphenidate – RVL Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 746,816 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aptensio xr, Concerta, Cotempla xr-odt, Covaryx, Covaryx covaryx, Daytrana, Diclovix m, Dyural 40 kit, Dyural 80 kit, Dyural 80-lm, Dyural lm kit, Eemt, Eemt eemt, Esterified estrogens and methyltestosterone, Esterified estrogens and methyltestosterone full strength esterified estrogens and methyltestosterone half strength, Estratest f.s., Estratest f.s. estratest h.s., Estratest fs estratest hs, Fenovar, Healthy mamabe well rounded, Hycodan, Hydrocodone bitartrate and homatropine methylbromide, Hydromet, Jornay pm, Metadate cd, Metadate er, Methylene blue, Methylin, Methylphenidate, Methylphenidate hydrochloride, Methylphenidate hydrochloride (la), Methylphenidate hydrochloride cd, Methylphenidate hydrochloride extended release, Methylphenidate transdermal system, Orthaphen, Perseris, Physicians ez use m-pred, Prenate elite, Prenate essential, Provayblue, Quillichew er, Quillivant, Relexxii, Ritalin, Varophen
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
241,502 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use